Will an mRNA cancer vaccine enter Phase 3 trials by end of 2026?

Moderna and BioNTech are racing personalized cancer vaccines through clinical stages. Phase 2 data from melanoma trials is promising.

Yes64%36%No

Volume

$2.42M

Traders

15.6K

Liquidity

$510K

Yes Price

$0.64

Probability History

Select Outcome

Prices include spread.

Select an outcome to start trading

Amount (USD)

You Pay—

Fee (1%, incl.)—

Trade Amount—

Shares—

Current Price—

Max Payout—

Max profit if correct—

Mock mode — no real funds used

Moderna and BioNTech are racing personalized cancer vaccines through clinical stages. Phase 2 data from melanoma trials is promising.

You can read comments as a guest, but posting requires an account

Loading comments…